Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5500 Wayzata Blvd Ste 1600 GOLDEN VALLEY MN 55416-1237 |
Tel: | N/A |
Website: | https://www.inspiresleep.com |
IR: | See website |
Key People | ||
Timothy P. Herbert President, Chief Executive Officer, Director | Richard J. Buchholz Chief Financial Officer | Philip J. Ebeling Chief Operating Officer |
Bryan K. Phillips Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary | John Rondoni Chief Technology Officer | Steven L. Jandrich Vice President of Human Resources |
Randall A. Ban Chief Commercial Officer | Charisse Y. Sparks Chief Medical Officer | Carlton Weatherby Chief Strategy Officer |
Business Overview |
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Inspire Medical Systems Inc revenues increased 53% to $624.8M. Net loss decreased 53% to $21.2M. Revenues reflect United States segment increase of 54% to $606.2M, All other countries segment increase of 43% to $18.6M. Lower net loss reflects Interest and dividend income increase from $5.1M to $20.6M (income), Interest expense decrease from $1.7M (expense) to $0K. |
Employees: | 1,011 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $6,363M as of Dec 31, 2023 |
Annual revenue (TTM): | $624.80M as of Dec 31, 2023 |
EBITDA (TTM): | -$37.43M as of Dec 31, 2023 |
Net annual income (TTM): | -$21.15M as of Dec 31, 2023 |
Free cash flow (TTM): | $1.02M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 30,297,311 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |